Pharmacology and clinical use of recombinant activated factor seven in neurosciences

Neurocritical Care

Volumn 6, Issue 2, 2007, Pages 149-157

  Hartmann, Matthias ^a   Sucker, Christoph ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Bleeding diathesis; Intracerebral hemorrhage; Neurosurgery; Recombinant activated factor VII; Trauma

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; FRESH FROZEN PLASMA; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICLOPIDINE; TIROFIBAN; VITAMIN K GROUP; WARFARIN;

ARTERY THROMBOSIS; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLUNT TRAUMA; BODY TEMPERATURE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INJURY; BRAIN TUMOR; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FIBRINOLYSIS; GLANZMANN DISEASE; HEART INFARCTION; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUNG EMBOLISM; MOLECULAR MODEL; NAUSEA; NEUROSCIENCE; NEUROSURGERY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PENETRATING TRAUMA; PEROPERATIVE CARE; PHYSIOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOCYTE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; TREATMENT FAILURE; VEIN THROMBOSIS; VOMITING;

BRAIN INJURIES; FACTOR VII; HEMOSTASIS; HEMOSTASIS, SURGICAL; HUMANS; INTRACRANIAL HEMORRHAGES; NEUROSURGICAL PROCEDURES; RECOMBINANT PROTEINS;

EID: 34250663910     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-007-0006-z     Document Type: Review

References (74)

1. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy to use predictor of 30-day mortality. Stroke 1993;24:987-93.
2. Broderick JP, Adams HP Jr, Barsan W et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999;30:905-15.
3. Mayer SA, Brun NC, Begtrup K et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
4. Negrier C, Lienhart A Overall experience with Novoseven. Blood Coagul Fibrinolysis 2000;11(suppl 1):19-24.
5. Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin Thromb Hemost 2001;27:373-83.
6. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005;93:1027-35.
7. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004;18:245-59.
8. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost 2004;92:738-46.
9. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000;11:S107-11.
10. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114:447-53.
11. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606-15.
12. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
13. Hoffman M. A cell-based model of haemostasis. Blood Rev 2003;17:1-5.
14. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004;15:521-38.
15. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15, tissue factor. Blood 2000;96(1):170-5.
16. Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004;32:S320-4.
17. Dahlback B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005;579:3310-16.
18. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-70.
19. Tollefsen DM, Majerus DW, Blank MK Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982;257:2162-69.
20. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6-15.
21. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-321.
22. Powner DJ, Hartwell EA, Hoots WK. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery 2005;57:823-831.
23. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989;87:2S-9S.
24. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84.
25. Hirsh J, Anand SS, Halperin JL, Fuster V. American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
26. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003;58:28-35.
27. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-8.
28. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737-40.
29. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-777.
30. Carr JA, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg 1999;40:659-66.
31. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-5.
32. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
33. Mannucci PM. Treatment of von Willebrand disease. N Engl J Med 2004;351:683-94.
34. Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology 2003:559-74.
35. Scharf RE. Congenital and acquired platelet function disorders. Hämostaseologie 2003;23:170-80.
36. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care 2005;9:S15-24.
37. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003;1:1138-9.
38. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-91.
39. Martinowitz U, Michaelson M. The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005;3:640-08.
40. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983;71:1836-41.
41. Dennis M. Outcome after brain haemorrhage. Cerebrovasc Dis 2003;16:9-13.
42. Brott T, Broderick J, Kothari R et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1-5.
43. Majumdar G, Savidge GF. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 1993;4:1031-3.
44. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994;47:36-40.
45. Arkin S, Cooper HA, Hutter JJ et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis 1998;28:93-98.
46. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263-7.
47. Freeman WD, Brott TG, Barrett KM et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79:1495-500.
48. Mendelow AD, Gregson BA, Fernandes HM et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005;365:387-97.
49. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997;94:12081-7.
50. Palmer JD, Francis DA, Roath OS, Francis JL, Iannotti F. Hyperfibrinolysis during intracranial surgery: effect of high dose aprotinin. J Neurol Neurosurg Psychiatry 1995;58:104-6.
51. Goh KY, Tsoi WC, Feng CS, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumors. J Neurol Neurosurg Psychiatry 1997;63:334-8.
52. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-77.
53. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003;53:34-8.
54. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. Report of three cases and review of the literature. J Neurosurg 2003;98:611-6.
55. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003;14(1):117-20.
56. Gerlach R, Marquardt G, Wissing H, Scharrer I, Raabe A, Seifert V. Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. J Neurosurg 2002;96:946-8.
57. Karadimov D, Binev K, Nachkov Y, Platikanov V. Use of activated recombinant Factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol 2003;15:330-2.
58. Hartmann M, Sucker C, Messing-Jünger M. Recombinant activated factor seven for the treatment of near fatal bleeding during paediatric brain tumour surgery. J Neurosurg 2006;104:55-8.
59. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003;2:CD001245.
60. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, Matthews J, Minhas P, Hutchinson PJ, Menon D, Downey SP, Kendall I, Clark J, Carpenter TA, Williams E, Persson L. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000;11:S117-20.
61. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003;17:223-31.
62. Schreiber MA, Holcomb JB, Rojkjaer R. Preclinical trauma studies of recombinant factor VIIa. Crit Care 2005;9:S25-8.
63. Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990;59:921-9.
64. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time, thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-57.
65. Martinowitz U, Holcomb JB, Pusateri AE et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001;50:721-9.
66. Grounds RM, Seebach C, Knothe C et al. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006;21:27-39.
67. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-18.
68. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002;49:S15-20.
69. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y. NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15.
70. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005;94:586-91.
71. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-64.
72. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295(3):293-8.
73. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002;94:1369-70.
74. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 2005;80:66-71.